Victor Marlar, MD
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1841400702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $439,639 of the $483,161 with a category attached, or 91.0%. Novo Nordisk accounts for 64.4% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $175,215 and has fallen 75.2% since, to $43,428 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 917 payments — averaging $526.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$311K
- AstraZeneca$61K
- Johnson & Johnson$56K
- Bayer$15K
- Tandem Diabetes Care, Inc.$8K
- Mannkind Corporation$7K
- plus $26K from 28 others
What the payments were for
- Consulting fees$11,5832%
- Speaking & faculty fees$439,63991%
- Travel & lodging$16,5683%
- Food & beverage$15,2513%
- Education$600%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 356 | $311,357 |
| AstraZeneca(2 entities) | 71 | $60,801 |
| Johnson & Johnson | 141 | $55,501 |
| Bayer | 23 | $14,582 |
| Tandem Diabetes Care, Inc. | 32 | $8,200 |
| Mannkind Corporation | 8 | $6,712 |
| Sanofi-aventis U.S. LLC | 13 | $5,896 |
| Abbott | 36 | $5,487 |
| Neurocrine Biosciences, Inc. | 14 | $5,203 |
| AbbVie | 5 | $3,047 |
| Insulet Corporation | 43 | $1,582 |
| Medtronic(2 entities) | 42 | $1,228 |
| IBSA Pharma Inc. | 5 | $1,055 |
| Lilly USA, LLC | 37 | $664 |
| Amgen(2 entities) | 26 | $488 |
| Corcept Therapeutics | 10 | $225 |
| Xeris Pharmaceuticals, Inc. | 7 | $147 |
| Ascendis Pharma Endocrinology Inc | 6 | $129 |
| Dexcom, Inc. | 6 | $119 |
| Antares Pharma, Inc. | 6 | $107 |
| Cequr Corporation | 3 | $102 |
| BETA Bionics, Inc. | 4 | $91 |
| Boehringer Ingelheim | 6 | $78 |
| Radius Health, Inc. | 2 | $62 |
| Recordati_rare_diseases_inc. | 3 | $59 |
| Ascensia Diabetes Care US Inc. | 2 | $47 |
| Nevro Corp. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Gilead | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$155,125
- RYBELSUS$111,311
- FARXIGA$59,779
- INVOKANA$54,518
- Tresiba$18,154
- Kerendia$14,328
- AFREZZA$6,458
- TZIELD$5,597
- t:slim X2 insulin pump$5,250
- CRENESSITY$4,779
- FREESTYLE LIBRE 3$3,251
- Synthroid$3,000
- Xultophy 100/3.6$2,848
- t-slim insulin pump$2,750
- Tirosint$2,000
- FreeStyle Libre Pro$1,375
- MINIMED 780G$294
- FreeStyle Libre$275
- FreeStyle Libre 2$125
- Omnipod$118
How this compares
$483,161 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,069 | $1,622,393 |
| Tresiba Flextouch U-200Insulin Degludec | 368 | $427,693 |
| MounjaroTirzepatide | 304 | $409,172 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 217 | $363,878 |
| JardianceEmpagliflozin | 213 | $226,948 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 213 | $226,739 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 160 | $180,632 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 57 | $163,802 |
| Tresiba Flextouch U-100Insulin Degludec | 133 | $102,871 |
| FarxigaDapagliflozin Propanediol | 99 | $96,630 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $91,145 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 83 | $79,695 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $77,578 |
| Novolog FlexpenInsulin Aspart | 158 | $72,636 |
| SynjardyEmpagliflozin/Metformin Hcl | 60 | $72,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Rybelsus, Novolog | $311,357 | $2,088,2291,386 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Glyxambi | $78 | $703,593688 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $664 | $501,426421 claims |
| AstraZenecaFarxiga | $60,801 | $96,63099 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $5,896 | $91,14572 claims |
| Johnson & JohnsonInvokana, Invokamet | $55,501 | $56,76458 claims |
| AbbVieSynthroid | $3,047 | $34,213353 claims |
| AmgenProlia | $488 | $29,73817 claims |
| BayerKerendia | $14,582 | $24,29119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Lauren BernsteinAsheville$307K
- Stephen WeinribAsheville$11K
- Hilary ThomasAsheville$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.